JNJessica AB van Nies

Jessica AB van Nies

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Jessica AB van Nies has a total of 12 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Interactive seminars or small group tutorials in preclinical medical education: results of a randomized controlled trial

    by Zuzana de Jong, Jessica AB van Nies, Sonja Wm Peters, Sylvia Vink, Friedo W Dekker, Albert Scherpbier

    Learning in small group tutorials is appreciated by students and effective in the acquisition of clinical problem-solving skills but poses financial and resource challenges. Interactive seminars, which accommodate large groups, might be an alternative. This study examines the educational effectiveness of small group tutorials and interactive seminars and students' preferences for and satisfaction with these formats.


  • Open Access

    TRAF1/C5polymorphism is not associated with increased mortality in rheumatoid arthritis: two large longitudinal studies

    by Jessica AB van Nies, Rute B Marques, Stella Trompet, Zuzana de Jong, Fina As Kurreeman, Rene Em Toes, J Wouter Jukema, Tom Wj Huizinga, Annette Hm van der Helm-Van Mil

    Introduction: Recently an association between a genetic variation in TRAF1/C5 and mortality from sepsis or cancer was found in rheumatoid arthritis (RA). The most prevalent cause of death, cardiovascular disease, may have been missed in that study, since patients were enrolled at an advanced disease stage. Therefore, we used an inception cohort of RA patients to investigate the association between TRAF1/C5 and cardiovascular mortality, and replicate the findings on all-cause mortality. As TRAF1/C5 associated mortality may not be restricted to RA, we also studied a large cohort of non-RA patients. Methods: 615 RA patients from the Leiden Early Arthritis Clinic (EAC) (mean follow-up 7.6 years) were genotyped for rs10818488. In addition 5634 persons enrolled in the PROspective Study of Pravastatin in the Elderly at Risk (mean follow-up 3.2 years) were genotyped for rs2416808 (R2 >0.99 with rs10818488). The life/death status was determined and for the deceased persons the cause of death was ascertained. Cox proportional hazards and regression models were used to assess hazard ratios (HR) and 95% confidence intervals (CI). Results: Seventy-seven RA patients died. The main death causes in RA patients were cardiovascular diseases (37.7%), cancer (28.6%) and death due to infections (9.1%). No association was observed between the rs10818488 susceptible genotype AA and cardiovascular mortality (HR 1.08 95%CI 0.54 to 2.15) and all-cause mortality (HR 0.81 95%CI 0.27 to 2.43). Similar findings were observed for rs2416808 susceptible genotype GG in the non-RA cohort (HR 0.99; 95%CI 0.79 to 1.25 and HR 0.89; 95%CI 0.64 to 1.25, respectively). Conclusions: The TRAF1/C5 region is not associated with an increased mortality risk.